Core Viewpoint - Shenzhen Hanyu Pharmaceutical Co., Ltd. (hereinafter referred to as "Hanyu Pharmaceutical") expects significant revenue growth in 2025, with projected revenue between 950 million to 980 million yuan, representing an increase of 60.96% to 66.05% year-on-year, and a net profit of 40 million to 50 million yuan, marking a turnaround from losses in the previous year [1] Group 1: Financial Performance - The company anticipates 2025 revenue of 950 million to 980 million yuan, a year-on-year growth of 60.96% to 66.05% [1] - Net profit is projected to be between 40 million to 50 million yuan, indicating a return to profitability [1] Group 2: Business Development - The growth in revenue is driven by the synergy between international formulations and active pharmaceutical ingredients, which are core engines of revenue growth [1] - The CRDMO (Contract Research, Development, and Manufacturing Organization) business is being actively advanced, contributing to the company's growth strategy [1] Group 3: Research and Innovation - Hanyu Pharmaceutical maintains a strong focus on innovation, with high R&D investment aimed at developing peptide innovative drugs, complex formulations, and cutting-edge technology platforms [1] - Significant progress has been made in multiple research projects, including the three-target innovative drug HY3003 and semaglutide, reinforcing the company's technological barriers [1] Group 4: Strategic Partnerships - The company is expanding its growth avenues through CRDMO business, leveraging its multi-national GMP certification and full industry chain capabilities [1] - Collaborations with companies like Carbon Cloud Peptide and Borui Pharmaceutical have been deepened, covering projects in areas such as antimicrobial peptides and oral peptides, successfully transforming technical accumulation into systematic service output capabilities [1]